A5090770917- SARS-CoV-2 and COVID-19 Research
- Infection Control in Healthcare
- Antibiotic Use and Resistance
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- Infection Control and Ventilation
- Nosocomial Infections in ICU
- Respiratory viral infections research
- COVID-19 and Mental Health
- Influenza Virus Research Studies
- Urinary Tract Infections Management
- Patient Satisfaction in Healthcare
- Antimicrobial Resistance in Staphylococcus
- Bacterial Identification and Susceptibility Testing
- COVID-19 and healthcare impacts
- SARS-CoV-2 detection and testing
- Long-Term Effects of COVID-19
- Fungal Infections and Studies
- Mosquito-borne diseases and control
- Viral gastroenteritis research and epidemiology
- Food Safety and Hygiene
- Antifungal resistance and susceptibility
- Sepsis Diagnosis and Treatment
- Dental Research and COVID-19
University of Arizona
2017-2025
Centers for Disease Control and Prevention
2010-2023
University of Miami
2022
Communities In Schools of Orange County
2019-2022
New York Proton Center
2022
Ann Arbor Center for Independent Living
2022
University of Richmond
2022
Oregon Medical Research Center
2022
Lindsay Unified School District
2022
Rocky Mountain University of Health Professions
2022
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic randomized placebo-controlled Phase III trials (1,2); however, the benefits of these for asymptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered real-world conditions, is less well understood. Using prospective cohorts health care personnel, first responders, other essential frontline workers* eight U.S....
Information is limited regarding the effectiveness of two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attenuating disease 2019 (Covid-19) when administered real-world conditions.
During December 14, 2020-April 10, 2021, data from the HEROES-RECOVER Cohorts,* a network of prospective cohorts among frontline workers, showed that Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines were approximately 90% effective in preventing symptomatic asymptomatic infection with SARS-CoV-2, virus causes COVID-19, real-world conditions (1,2). This report updates vaccine effectiveness (VE) estimates including all available through August examines whether VE differs for adults...
In 2011 and 2013, the National Blood Collection Utilization Survey (NBCUS) revealed declines in blood collection transfusion United States. The objective of this study was to describe services 2015.The 2015 NBCUS distributed all US centers, hospitals performing at least 1000 surgeries annually, a 40% random sample 100 999 annually. Weighting imputation were used generate national estimates for units components collected, deferred, distributed, transfused, outdated.Response rates 78.4%...
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) May 12, 2021, and children 5-11 November 2, 2021 (1-4). Real-world data effectiveness (VE) these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant United States December early investigations of VE demonstrated a decline protection against symptomatic...
The purpose of this document is to highlight practical recommendations assist acute-care hospitals in prioritization and implementation strategies prevent healthcare-associated infections through hand hygiene. This updates the Strategies Prevent Healthcare-Associated Infections Acute Care Hospitals Hand Hygiene, published 2014. expert guidance sponsored by Society for Healthcare Epidemiology (SHEA). It product a collaborative effort led SHEA, Infectious Diseases America, Association...
Previously published guidelines provide comprehensive recommendations for hand hygiene in healthcare facilities. The intent of this document is to highlight practical a concise format, update with the most current scientific evidence, and elucidate topics that warrant clarification or more robust research. Additionally, designed assist facilities implementing adherence improvement programs, including efforts optimize product use, monitor report back data, promote behavior change. This expert...
We report on 9 cases of male-to-female sexual transmission Zika virus in the United States occurring January-April 2016. This summarizes new information about both timing exposure and symptoms sexually transmitted disease, results semen testing for from 2 male travelers.
Since the publication of “A Compendium Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals” 2008, prevention healthcare-associated infections (HAIs) has become a national priority. Despite improvements, preventable HAIs continue occur. The 2014 updates were created provide acute care hospitals with up-to-date, practical, expert guidance assist prioritizing and implementing their HAI efforts. They are product highly collaborative effort led by Society for Healthcare...
Influenza virus infections declined globally during the COVID-19 pandemic. Loss of natural immunity from lower rates influenza infection and documented antigenic changes in circulating viruses may have resulted increased susceptibility to 2021-2022 season.To compare risk among household contacts patients with season seasons before pandemic US.This prospective study transmission enrolled households 2 states (2017-2020) 4 US season. Primary cases were individuals earliest laboratory-confirmed...
Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus disease 2019 (COVID-19); however, rebound after treatment has been reported. We compared symptom and viral dynamics in individuals with COVID-19 who completed N/R similar untreated individuals. Methods identified symptomatic participants tested acute respiratory syndrome 2–positive were eligible a household transmission study. Index cases ambulatory settings their households contacts enrolled. collected...
Importance Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, 5 to 11 October 12, 2022; however, data demonstrating effectiveness of bivalent are limited. Objective To assess against SARS-CoV-2 infection symptomatic among adolescents. Design, Setting, Participants Data period 4, January 31, 2023, combined from 3 prospective cohort studies (6 sites total) used estimate vaccine 17 years. A total 2959 participants...
Previously published guidelines provide comprehensive recommendations for hand hygiene in healthcare facilities. The intent of this document is to highlight practical a concise format, update with the most current scientific evidence, and elucidate topics that warrant clarification or more robust research. Additionally, designed assist facilities implementing adherence improvement programs, including efforts optimize product use, monitor report back data, promote behavior change. This expert...
The most common methods for evaluating interventions to reduce the rate of new Staphylococcus aureus (MRSA) infections in hospitals use segmented regression or interrupted time-series analysis. We describe approaches introduced different healthcare units at times. compare fitting a Poisson each hospital unit with pooling individual estimates by inverse variance. An extension this approach accommodate potential heterogeneity allows be calculated from single statistical model: 'stacked' model....
The Arizona Healthcare, Emergency Response, and Other Essential workers Study (AZ HEROES) aims to examine the epidemiology of SARS-CoV-2 infection COVID-19 illness among adults with high occupational exposure risk.
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the virus that causes COVID-19) randomized placebo-controlled Phase III trials persons aged 12-17 years (referred to as adolescents this report) (1); however, data on real-word effectiveness (VE) among are limited (1-3). As of December 2021, the Pfizer-BioNTech is approved by Food and Drug Administration (FDA) for 16-17 under FDA emergency use authorization those 12-15...
As population immunity to SARS-CoV-2 evolves and new variants emerge, the role accuracy of antigen tests remain active questions. To describe recent test performance, detection by testing was compared with that reverse transcription-polymerase chain reaction (RT-PCR) viral culture during November 2022-May 2023. Participants who were enrolled in a household transmission study completed daily symptom diaries collected two nasal swabs (tested for via RT-PCR, culture, tests) each day 10 days...
To prevent unintentional transmission of bloodborne pathogens through organ transplantation, procurement organizations (OPOs) screen potential donors by serologic testing to identify human immunodeficiency virus (HIV) and hepatitis C (HCV) infection. Newly acquired infection, however, may be undetectable testing. Our objective was estimate the incidence undetected infection among assess significance risk reductions conferred nucleic acid (NAT) versus serology alone. We calculated prevalence...